Skip to content
Screener

MBX Biosciences, Inc. MBX Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
$1.29M-58.7%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$1.22M-20.1%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$1.56M-42.4%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$2.22M-49.3%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.05M-45.4%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$3.27B+742%
Enterprise value$3.22B+826%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 9:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210593
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense5,4841,839
Non cash operating lease expense3429
Accretion and amortization of marketable securities, net(579)(1,343)
Depreciation expense6477
Changes in operating assets and liabilities:
Prepaid expenses and other current assets(725)1,648
Accounts payable3,972(1,564)

Item 1. Financial Statements.

FAQ

What is MBX Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments?
MBX Biosciences, Inc. (MBX) reported accretion (amortization) of discounts and premiums, investments of $579K in Q1 2026.
How has MBX Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
MBX Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 56.9% year-over-year, from $1.34M to $579K.
What does accretion (amortization) of discounts and premiums, investments mean?
This reflects the non-cash adjustment to the carrying value of investment securities held by the company, accounting for the amortization of premiums or accretion of discounts over the life of the instrument. It reconciles the difference between the purchase price and the face value of debt securities. This adjustment is necessary to align reported interest income with the effective interest method.

Ask your AI about MBX Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude